Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma
JCO Precision Oncology · 2026-07 · 10 (7)
DOI: 10.1200/po-25-00520 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-07. Verfasst von Soji Toda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Surgery, Kanagawa Cancer Center, Kanagawa, Japan. Hauptthemen laut MEDLINE: Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Most thyroid cancers are initiated by alterations activating the mitogen-activated protein kinase (MAPK) pathway and progress via additional genomic events. Because papillary thyroid carcinoma (PTC) generally has a favorable prognosis and rarely advances, knowledge about later-acquired genomic alterations and their impact on prognosis is limited. MATERIALS AND METHODS This study is a real-world database study using a nationwide database that contains clinical data and comprehensive genomic profiling (CGP) test results. We investigated gene alterations and their impact on prognosis in advanced PTC. RESULTS The study included 322 patients with advanced papillary carcinoma who underwent CGP tests for drug selection between June 2019 and April 2024. Metastases were present in 96% of cases, and 70% received systemic therapy. The most common genomic abnormalities were mutations in the TERT promoter and BRAF . BRAF alterations were mutually exclusive with RBM10 and other MAPK pathway genes such as RET, NRAS, and NTRK1 , but co-occurred with TERT and AKT1 . The MAPK pathway had the highest frequency of alterations (96%), followed by the phosphoinositide 3-kinase (PI3K; 23%), cell cycle (13%), and p53 (11%) pathways. Survival analysis showed that alterations in PTEN and CDKN2A were independent poor prognostic factors. Patients harboring alterations in the PI3K or cell cycle pathway showed significantly shorter overall survival. CONCLUSION Our study clarified the frequency, co-occurrence, and exclusivity of gene alterations in advanced PTC. Alterations in the PI3K or cell cycle pathways are linked to poor prognosis, and therapies targeting these pathways may warrant further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Endocrine Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
- Department of Cancer Genome Medicine, Kanagawa Cancer Center, Kanagawa, Japan.
- Division of Advanced Cancer Therapeutics, Kanagawa Cancer Center Research Institute, Kanagawa, Japan.
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Kanagawa, Japan.
- Department of Pathology, Kanagawa Cancer Center, Kanagawa, Japan.
- Department of Surgery, Yokohama City University, Kanagawa, Japan.
ORCID-Profile: Soji Toda, Yukihiko Hiroshima, Hiroyuki Iwasaki, Mei Kadoya, Yoichiro Okubo, Aya Saito, Katsuhiko Masudo
Zitieren
APA
Toda, S., Hiroshima, Y., Iwasaki, H., Kadoya, M., Suzuki, C., Yamazaki, H., Okubo, Y., Saito, A., & Masudo, K. (2026). Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma. JCO Precision Oncology, 10(7). https://doi.org/10.1200/po-25-00520
Vancouver
Toda S, Hiroshima Y, Iwasaki H, Kadoya M, Suzuki C, Yamazaki H, et al. Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma. JCO Precision Oncology. 2026;10(7). doi:10.1200/po-25-00520
BibTeX
@article{Toda2026,
author = {Toda, Soji and Hiroshima, Yukihiko and Iwasaki, Hiroyuki and Kadoya, Mei and Suzuki, Chihiro and Yamazaki, Haruhiko and Okubo, Yoichiro and Saito, Aya and Masudo, Katsuhiko},
title = {Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {7},
doi = {10.1200/po-25-00520}
}
EUVIMED